Citadel Advisors
ELVN icon

Citadel Advisors’s Enliven Therapeutics ELVN Stock Holding History

Citadel Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.59M Buy
91,500
+73,800
+417% +$2.04M ﹤0.01% 4919
2025
Q4 		$273K Buy
+17,700
New +$353K ﹤0.01% 10357
2025
Q2 		– Sell
-900
Closed -$17.7K – 13226
2025
Q1 		$17.7K Buy
900
+600
+200% +$12.9K ﹤0.01% 13229
2024
Q4 		$6.75K Sell
300
-200
-40% -$5.18K ﹤0.01% 13779
2024
Q3 		$12.8K Sell
500
-100
-17% -$2.32K ﹤0.01% 13087
2024
Q2 		$14K Buy
+600
New +$12.6K ﹤0.01% 12907
2023
Q2 		– Sell
-250
Closed -$5.47K – 14557
2023
Q1 		$5.47K Sell
250
-4,450
-95% -$90.5K ﹤0.01% 13869
2022
Q4 		$76.9K Sell
4,700
-11,225
-70% -$179K ﹤0.01% 11569
2022
Q3 		$145K Buy
+15,925
New +$94K ﹤0.01% 10740

Other funds holding ELVN

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return